Brief Report: Malignancies in Adults Living With HIV in Asia.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 03 2019
01 03 2019
Historique:
pubmed:
12
12
2018
medline:
2
11
2019
entrez:
12
12
2018
Statut:
ppublish
Résumé
Hematological malignancies have continued to be highly prevalent among people living with HIV (PLHIV). This study assessed the occurrence of, risk factors for, and outcomes of hematological and nonhematological malignancies in PLHIV in Asia. Incidence of malignancy after cohort enrollment was evaluated. Factors associated with development of hematological and nonhematological malignancy were analyzed using competing risk regression and survival time using Kaplan-Meier. Of 7455 patients, 107 patients (1%) developed a malignancy: 34 (0.5%) hematological [0.08 per 100 person-years (/100PY)] and 73 (1%) nonhematological (0.17/100PY). Of the hematological malignancies, non-Hodgkin lymphoma was predominant (n = 26, 76%): immunoblastic (n = 6, 18%), Burkitt (n = 5, 15%), diffuse large B-cell (n = 5, 15%), and unspecified (n = 10, 30%). Others include central nervous system lymphoma (n = 7, 21%) and myelodysplastic syndrome (n = 1, 3%). Nonhematological malignancies were mostly Kaposi sarcoma (n = 12, 16%) and cervical cancer (n = 10, 14%). Risk factors for hematological malignancy included age >50 vs. ≤30 years [subhazard ratio (SHR) = 6.48, 95% confidence interval (CI): 1.79 to 23.43] and being from a high-income vs. a lower-middle-income country (SHR = 3.97, 95% CI: 1.45 to 10.84). Risk was reduced with CD4 351-500 cells/µL (SHR = 0.20, 95% CI: 0.05 to 0.74) and CD4 >500 cells/µL (SHR = 0.14, 95% CI: 0.04 to 0.78), compared to CD4 ≤200 cells/µL. Similar risk factors were seen for nonhematological malignancy, with prior AIDS diagnosis showing a weak association. Patients diagnosed with a hematological malignancy had shorter survival time compared to patients diagnosed with a nonhematological malignancy. Nonhematological malignancies were common but non-Hodgkin lymphoma was more predominant in our cohort. PLHIV from high-income countries were more likely to be diagnosed, indicating a potential underdiagnosis of cancer in low-income settings.
Sections du résumé
BACKGROUND
Hematological malignancies have continued to be highly prevalent among people living with HIV (PLHIV). This study assessed the occurrence of, risk factors for, and outcomes of hematological and nonhematological malignancies in PLHIV in Asia.
METHODS
Incidence of malignancy after cohort enrollment was evaluated. Factors associated with development of hematological and nonhematological malignancy were analyzed using competing risk regression and survival time using Kaplan-Meier.
RESULTS
Of 7455 patients, 107 patients (1%) developed a malignancy: 34 (0.5%) hematological [0.08 per 100 person-years (/100PY)] and 73 (1%) nonhematological (0.17/100PY). Of the hematological malignancies, non-Hodgkin lymphoma was predominant (n = 26, 76%): immunoblastic (n = 6, 18%), Burkitt (n = 5, 15%), diffuse large B-cell (n = 5, 15%), and unspecified (n = 10, 30%). Others include central nervous system lymphoma (n = 7, 21%) and myelodysplastic syndrome (n = 1, 3%). Nonhematological malignancies were mostly Kaposi sarcoma (n = 12, 16%) and cervical cancer (n = 10, 14%). Risk factors for hematological malignancy included age >50 vs. ≤30 years [subhazard ratio (SHR) = 6.48, 95% confidence interval (CI): 1.79 to 23.43] and being from a high-income vs. a lower-middle-income country (SHR = 3.97, 95% CI: 1.45 to 10.84). Risk was reduced with CD4 351-500 cells/µL (SHR = 0.20, 95% CI: 0.05 to 0.74) and CD4 >500 cells/µL (SHR = 0.14, 95% CI: 0.04 to 0.78), compared to CD4 ≤200 cells/µL. Similar risk factors were seen for nonhematological malignancy, with prior AIDS diagnosis showing a weak association. Patients diagnosed with a hematological malignancy had shorter survival time compared to patients diagnosed with a nonhematological malignancy.
CONCLUSIONS
Nonhematological malignancies were common but non-Hodgkin lymphoma was more predominant in our cohort. PLHIV from high-income countries were more likely to be diagnosed, indicating a potential underdiagnosis of cancer in low-income settings.
Identifiants
pubmed: 30531303
doi: 10.1097/QAI.0000000000001918
pmc: PMC6375805
mid: NIHMS1512081
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
301-307Subventions
Organisme : NIAID NIH HHS
ID : U01 AI069907
Pays : United States
Références
BMC Med. 2014 Jan 08;12:3
pubmed: 24400922
HIV Med. 2010 Sep;11(8):519-29
pubmed: 20345881
Curr Opin HIV AIDS. 2017 Jan;12(1):89-95
pubmed: 27607593
Leuk Lymphoma. 2011 Aug;52(8):1597-600
pubmed: 21657953
BMC Cancer. 2015 Mar 16;15:133
pubmed: 25885746
AIDS. 2014 Sep 24;28(15):2313-8
pubmed: 25111081
Lancet Oncol. 2009 Dec;10(12):1152-9
pubmed: 19818686
Int J Cancer. 2016 Sep 15;139(6):1209-16
pubmed: 27098265
AIDS. 2012 Nov 13;26(17):2223-31
pubmed: 22951631
Oncology. 2012;82(5):269-74
pubmed: 22538443
Clin Infect Dis. 2014 Jun;58(11):1599-606
pubmed: 24523217
Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S96-103
pubmed: 25486964
J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):174-9
pubmed: 15671802
Ann Intern Med. 2018 Jun 19;168(12):866-873
pubmed: 29801099
Antivir Ther. 2009;14(8):1065-74
pubmed: 20032536
J Acquir Immune Defic Syndr. 2018 Jul 1;78(3):329-337
pubmed: 29543636
AIDS. 2018 Sep 17;32(18):2777-2786
pubmed: 30234606
Lancet HIV. 2017 Nov;4(11):e495-e504
pubmed: 28803888
PLoS One. 2014 Apr 23;9(4):e94768
pubmed: 24760049
J Infect Public Health. 2015 Jan-Feb;8(1):1-10
pubmed: 25294086
Medicine (Baltimore). 2016 Sep;95(37):e4850
pubmed: 27631245
AIDS Res Hum Retroviruses. 2016 Aug;32(8):772-81
pubmed: 27030657
J Fungi (Basel). 2017 Dec 02;3(4):
pubmed: 29371581